It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Esophageal cancer has a strikingly low survival rate mainly due to the lack of diagnostic markers for early detection and effective therapies. In the U.S., 75% of individuals diagnosed with esophageal squamous cell carcinoma (ESCC) are of African descent. African American ESCC (AA ESCC) is particularly aggressive, and its biological underpinnings remain poorly understood. We sought to identify the genomic abnormalities by conducting whole exome sequencing of 10 pairs of matched AA esophageal squamous cell tumor and control tissues. Genomic analysis revealed diverse somatic mutations, copy number alterations (SCNAs), and potential cancer driver genes. Exome variants created two subgroups carrying either a high or low tumor mutation burden. Somatic mutational analysis based on the Catalog of Somatic Mutations in Cancer (COSMIC) detected SBS16 as the prominent signature in the high mutation rate group suggesting increased DNA damage. SBS26 was also detected, suggesting possible defects in mismatch repair and microsatellite instability. We found SCNAs in multiple chromosome segments, encoding MYC on 8q24.21, PIK3CA and SOX2 on 3q26, CCND1, SHANK2, CTTN on 11q13.3, and KRAS on 12p12. Amplifications of EGFRvIII and EGFRvIVa mutants were observed in two patients, representing a novel finding in ESCC that has potential clinical relevance. This present exome sequencing, which to our knowledge, represents the first comprehensive exome analysis exclusively in AA ESCC, and highlights novel mutated loci that might explain the aggressive nature of AA ESCC and lead to the development of diagnostic and prognostic markers as well as therapeutic targets.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Veterans Affairs Medical Center, Institute for Clinical Research, Washington, USA (GRID:grid.413721.2) (ISNI:0000 0004 0419 317X)
2 Dartmouth-Hitchcock Medical Center, Lebanon, USA (GRID:grid.413480.a) (ISNI:0000 0004 0440 749X)
3 Queromatics, Laveen, USA (GRID:grid.413480.a)
4 Veterans Affairs Medical Center, Hepatology and Gastroenterology, Washington, USA (GRID:grid.413721.2) (ISNI:0000 0004 0419 317X)
5 Georgetown University, Lombardi Comprehensive Cancer Center, Washington, USA (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644)
6 Veterans Affairs Medical Center, Pathology and Laboratory Service, Washington, USA (GRID:grid.413721.2) (ISNI:0000 0004 0419 317X)
7 Veterans Affairs Medical Center, Institute for Clinical Research, Washington, USA (GRID:grid.413721.2) (ISNI:0000 0004 0419 317X); Veterans Affairs Medical Center, Hematology and Medical Oncology, Washington, USA (GRID:grid.413721.2) (ISNI:0000 0004 0419 317X)